290 (82.six) 50 (82.0) 247 (85.two) (eight.0) 43 (4.eight) 0.79(0.38.64) .00 8 (33.6) 233 (66.4) 07 (90.7) 90 (8.five) (9.three) 43 (8.5) 2.20 (.09.45) .0.Getting concerned HIV may possibly pose a threat to family members Yes
290 (82.6) 50 (82.0) 247 (85.2) (8.0) 43 (4.eight) 0.79(0.38.64) .00 8 (33.6) 233 (66.four) 07 (90.7) 90 (eight.five) (9.3) 43 (eight.five) two.20 (.09.45) .0.Becoming concerned HIV may perhaps pose a threat to members of the family Yes No 268 (76.eight) 82 (23.two) 229 (85.4) 67 (eight.7) 39 (4.six) 5 (8.3) .32(0.68.53) .0.Sex with HIVpositive companion in prior 6 months Yes No 295 (84.0) 56 (six.0) 253 (85.8) 44 (78.6) 42 (4.2) two (two.4) .64(0.80.37) .0.Frequency of condom use in prior six months Just about every time The majority of the time In some cases Never ever 236 (80.0) two (7.) 3 (4.four) 25 (eight.5) 20 (85.2) 20 (95.two) 2 (92.three) 20 (80.0) 35 (four.eight) (four.eight) (7.7) 5 (20.0) .00 three.48(0.456.79) two.09(0.266.58) 0.70 (0.25.98)0.0.23 0.49 0.50 0.Selfperceived likelihood of contracting HIV from HIVpositive companion Probably Unlikely 09 (three.) 242 (68.9) 0 (92.7) PRIMA-1 chemical information pubmed ID:https://www.ncbi.nlm.nih.gov/pubmed/20874419 96 (8.0) eight (7.3) 46 (9.0) 2.96 (.35.52) .Abbreviations: HIV, human immunodeficiency virus; AIDS, acquired immune deficiency syndrome; PrEP, preexposure prophylaxis; CI, self-assurance interval; OR, odds ratio. doi:0.37journal.pone.0067392.tPLOS A single plosone.orgWillingness to make use of PrEP in HIVDiscordant CouplesTable 4. Relationship in between awareness ofuse ofattitudes toward PrEP and willingness to make use of PrEP.Willing to use oral PrEP Things N Yes, n No, n, OR (95 CI)P value0.Ever heard of vaginal microbicides Yes No Ever heard of PEP Yes No Ever heard of PrEP Yes No 0 (2.eight) 34 (97.two) eight (80.0) 289 (84.8) 2 (20.0) 52 (5.2) 0.72(0.five.49) .00 34 (9.7) 37 (90.three) 28 (82.four) 269 (84.9) 6 (7.6) 48 (5.) 0.83 (0.33.two) .00 27 (7.7) 324 (92.3) 26 (96.3) 27 (83.6) (three.7) 53 (6.4) 5.09 (0.688.29) .0.0.Ever taken medicine to stop sexually transmitted disease Yes No 7 (two.0) 344 (98.0) six (85.7) 29 (84.6) (four.3) 53 (5.4) .09 (0.three.26) .0.Worrying about being discriminated against by other people because of oral PrEP use Yes No 92 (54.7) 59 (45.three) 45 (75.5) 52 (95.six) 47 (24.5) 7 (four.four) .00 7.04 (three.086.67)0.Abbreviations: PEP, postexposure prophylaxis; PrEP, preexposure prophylaxis; CI, self-assurance interval; OR, odds ratio. doi:0.37journal.pone.0067392.tWillingness to use oral PrEP and concerns associated with its useA total of 297 participants (84.six ) have been willing to use oral PrEP if verified each successful and protected. The remaining 54 participants (five.4 ) have been unwilling to make use of oral PrEP due to the fact three (57.four ) believed they have been at no risk of contracting HIV, or 28 (5.9 ) had been concerned about its security, or 2 (22.2 ) doubted its efficacy. Amongst participants prepared to utilize oral PrEP, 258 (86.8 ) have been concerned about its efficacy, 249 (83.8 ) were concerned about its security, 90 (64.0 ) had been concerned about its price, and 45 have been concerned about its availability (5.two ). With regards to social issues, 3 (38.0 ) participants had no worry of disclosing their use of PrEP to others.Multivariate logistic regression analysis of components linked with willingness to use oral PrEPIn multivariate logistic regression evaluation, willingness to use oral PrEP was coded as “”, and unwillingness to utilize oral PrEP was coded as “0”. Variables that were substantial (P,0.two) within the univariate evaluation had been entered in to the initial multivariate logistic model; these variables integrated “age”, “ethnicity”, “monthly household income”, “having a very good awareness of HIVAIDS”, “sex with HIVpositive companion inside the preceding six months”, “awareness of vaginal microbicides”, “it is difficult to avoid HIVAIDS when cohabiting using a HIVpositive partner”, “selfperceived likelihood of contracting HIV from an HIVpositiveAcceptability of oral PrEP in.